NCT06086626 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Gram-Negative Bacterial Infections

Interventions

DRUG

Cefiderocol

Administered via intravenous (IV) infusion

DRUG

Standard of Care

Antibiotics selected by the investigator based on the participant's symptoms, in accordance with local standards

Trial Locations (4)

Chang Gung Memorial Hospital, Linkou Department of Pediatrics, Taoyuan

Tygerberg Hospital, Cape Town

Duke University, Durham

Arkansas Children's Hospital, Little Rock